Belongs to the class of protein kinase inhibitors other antineoplastic agents. Sunitinib inhibits receptor tyrosine kinases including VEGF1 VEGF2 PDGFa PDGF-v KIT receptor and FLT3 receptor.

Mechanism Of Action Of Sunitinib In Endothelial Cells Expressing The Download Scientific Diagram

Sutent is indicated for the treatment of unresectable andor metastatic malignant gastrointestinal stromal tumour GIST in adults after failure of imatinib treatment due to resistance or intolerance.

Sutent mechanism of action. Epub 2009 Jan 21. Proc Natl Acad Sci U S A. Receptor tyrosine kinases are implicated in a number of cell-cell signaling pathways governing angiogenesis cell division and growth and cell survival.

Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 55 and 03 times the clinical systemic exposure AUC at the recommended. SUTENT is a kinase inhibitor indicated for the treatment of. This agent also inhibits the phosphorylation of Fms-related.

Sunitinib is an indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Votrient Treatment for Renal Cell Cancer and Soft Tissue Sarcoma - Votrient is a type of targeted therapy that contains multityrosine kinase inhibitor of the VEGF vascular endothelial growth factor receptor. 11 treatment of adult patients with advanced renal cell carcinoma RCC.

Authors Alfredo Carrato Mena 1 Enrique Grande Pulido Carmen Guillen-Ponce. Sutent is an orally-available small-molecule multiple receptor tyrosine kinase inhibitor. Sutent sutinib is a drug that interferes with among other mechanisms of action the so-called angiogenesis which plays an important role in tumour growth.

Sunitinib was the first cancer drug simultaneously approved for two different. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 VEGFR2 platelet-derived growth factor receptor b PDGFRb and c-kit thereby inhibiting angiogenesis and cell proliferation. Renal cell carcinoma is believed to arise from a multistep process where the evolving cell acquires mutations within proto-oncogenes tumor-suppressor genes and other genes that regulate cell proliferation.

By disrupting these systems Sutent inhibits the ability of tumor cells to divide and grow. SUTENT is a kinase inhibitor indicated for. Sutent - Clinical Pharmacology Mechanism of Action.

Blocking the growth of tumour cells is the main function of this drug. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor. Sunitinib marketed as Sutent by Pfizer and previously known as SU11248 is an oral small-molecule multi-targeted receptor tyrosine kinase RTK inhibitor that was approved by the FDA for the treatment of renal cell carcinoma RCC and imatinib-resistant gastrointestinal stromal tumor GIST on January 26 2006.

Gastrointestinal stromal tumor GIST after disease progression on or intolerance to imatinib mesylate. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Affiliation 1 Medical.

It blocks the proteins and other targets within the cell-like tyrosine kinases which are located on the surface. 11 Advanced renal cell. Multikinase inhibitor including VEGF and PDGF receptor tyrosine kinases some of which are implicated in tumor growth angiogenesis and metastasis.

SUTENT sunitinib malate capsules are supplied as printed hard shell capsules containing sunitinib malate equivalent to 125 mg 25 mg 375 mg or 50 mg of sunitinib together with mannitol croscarmellose sodium povidone K-25 and magnesium stearate as inactive ingredients. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10-14. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Based on findings from animal studies and its mechanism of action SUTENT can cause fetal harm when administered to pregnant woman. This term is used by biologists to de-scribe the formation of new blood vessels and these are essential for the growth of tumours. Treatment of adult patients with gastrointestinal stromal tumor GIST after disease progression on or intolerance to imatinib mesylate.

Sutent sunitinib malate an oral multi-kinase inhibitor and works by blocking multiple molecular targets implicated in the growth proliferation and spread of cancer. Sunitinib is a small molecule that inhibits. View Sutent mechanism of action for pharmacodynamics and pharmacokinetics details.

2010 Jan21 Suppl 1S3-11. L01XE04 - sunitinib. Used in the treatment of cancer.

Metastatic renal cell carcinoma MRCC Sutent is indicated for the treatment of advancedmetastatic renal cell carcinoma MRCC in adults. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. Two Sutent targets vascular endothelial growth factor receptor VEGFR and platelet-derived growth factor receptor PDGFR are expressed by many types of.

Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases RTKs some of which are implicated in tumor growth pathologic angiogenesis and metastatic progression of cancer.